Interactive influences of peroxisome proliferator-activated receptor α activation and glucocorticoids on pancreatic beta cell compensation in insulin resistance induced by dietary saturated fat in the rat 
Introduction
The liver is a major target tissue for the glucocorticoids, which increase hepatic glucose production by stimulating gluconeogenesis (reviewed in [1] ). This action is important for maintaining glycaemia in starvation, where increased fatty acid oxidation spares pyruvate for gluconeogenesis via inhibition of the pyruvate dehydrogenase complex, and provides ATP and cofactors for gluconeogenesis. However, glucocorticoids at excessive levels can induce insulin resistance and precipitate glucose intolerance [1] [2] [3] . Lowering of circulating fatty acid concentrations reverses insulin resistance in human subjects treated with glucocorticoids [4] . Thus, either lipid oxidation and/or altered lipid signalling is involved in the mechanism by which glucocorticoid excess induces whole-body insulin resistance. The PPAR (peroxisome proliferator-activated receptor) subtypes (α, γ, δ) are lipid-responsive transcription factors that regulate lipid storage and oxidation. PPARα is highly expressed in liver [5] , where its activation promotes hepatic fatty acid oxidation [6, 7] . Glucocorticoids induce PPARα expression in cultured hepatocytes and intact liver in rodents [8] . Importantly, PPARα is required for hepatic insulin resistance to be induced in response to the administration of the synthetic glucocorticoid dexamethasone [9] . Increased dietary saturated fat can also elicit the development of insulin resistance [10] [11] [12] (reviewed in [13, 14] ). However, contrasting with the facilitatory role of PPARα in the induction of hepatic insulin resistance in response to glucocorticoids, PPARα activation improves insulin sensitivity in the high dietary fat model of insulin resistance [15, 16] . The differences in the influence of PPARα activation on insulin resistance induced by glucocorticoids and that induced by high-saturated-fat feeding may reflect the underlying mechanisms invoking insulin resistance in these two states, namely a more hepatocentric action in glucocorticoid-induced insulin resistance, contrasting with a wider influence of high-fat feeding to induce tissue lipid accumulation with resultant dysregulation of insulin signalling. Importantly, there is increasing evidence that long-term lipid sensing by the pancreatic beta cell could be coordinated through the expression and/or activity of PPARα [17, 18] (reviewed in [19, 20] ). We have recently established that activation of PPARα can oppose insulin hypersecretion elicited by high-fat feeding via stable long-term effects exerted on islet function [15] .
In the present study, we therefore sought to elucidate whether excess glucocorticoids and increased dietary lipid act synergistically to impair glucose tolerance and, if so, whether PPARα activation has an adverse or beneficial effect on glucose tolerance. We analysed our data in relation to effects of these manipulations on glucose-stimulated insulin secretion (GSIS), the induction of insulin resistance in the intact animal and direct long-term adaptations of islet function. By extending our studies to islet perifusions, we exclude the influence of circulating factors that may signal changes in insulin action in tissues other than the islet.
Materials and methods

Materials
General Laboratory reagents were from Roche Diagnostics (Lewes, UK) or from Sigma (Poole, UK). Kits for determination of insulin (ELISA, rat insulin as standard), glucose (glucose oxidase) and leptin (ELISA, rat leptin as standard) were from Mercodia (Uppsala, Sweden), Roche Diagnostics and Metachem Diagnostics (Northampton, UK). Dexamethasone (sodium phosphate) was obtained from David Bull Laboratories (Warwick, UK). Mini-osmotic pumps were purchased from Charles River (Margate, UK). WY14643 (pirinixic acid) was purchased from Sigma.
Animals
All studies were conducted in adherence to the regulations of the United Kingdom Animal Scientific Procedures Act (1986). Female Wistar rats (200-250 g) were purchased from Charles River Laboratories. Rats were subjected to a standard light (08:00-20:00 h)-dark (20:00-08:00 h) cycle in a temperature-controlled room (21±2°C). The rats were housed in individual cages and were given free access to water and to a semi-synthetic diet high in saturated fat for 4 weeks (for details see [11, 12] ) (HF group). Dexamethasone (100 μg kg −1 body weight day
; 5 days) was administered to HF rats via indwelling osmotic pumps [21] for the last 5 days of the 4-week period of high-fat feeding (HF-DEX group). An initial priming dose (0.1 mg) of dexamethasone was given by subcutaneous injection before minipump implantation. This procedure leads to almost total suppression of endogenous corticosterone levels (results not shown). Sham operations involving incision and manipulation under anaesthesia identical to the procedure for implantation of the osmotic minipump were undertaken on a second (control) group of rats. The PPARα agonist WY14643 (or vehicle) was administered as a single intraperitoneal injection (50 mg kg −1 body weight), and rats were sampled after 24 h [15, 22] (HF-WY and HF-DEX-WY groups). We used acute (24 h) exposure to WY14643, rather than longer term repeated administration over several days, since we have previously demonstrated that activation of PPARα by a single bolus dose of WY14643 opposes insulin hypersecretion elicited by high-fat feeding [15] , and therefore the present study can be compared directly with our earlier studies.
Intravenous glucose tolerance tests
Glucose was administered as an intravenous bolus (0.5 g glucose kg −1 body weight; 150 μl per 100 g body weight) to conscious, unrestrained rats in the postabsorptive state 6 h after food withdrawal [12, 23] . Glucose was injected via a chronic indwelling jugular cannula and blood samples (100 μl) were withdrawn at intervals from the indwelling cannula, which was flushed with saline after the injection of glucose to remove residual glucose. Samples of whole blood (50 μl) were deproteinised with ZnSO 4 /Ba(OH) 2 and centrifuged (10,000 g) at 4°C, and the supernatant was retained for subsequent assay of blood glucose. The remaining blood sample was immediately centrifuged (10,000 g) at 4°C, and plasma was stored at −20°C until assayed for insulin. The acute insulin response (AIR) was calculated as the mean of suprabasal 2-min and 5-min plasma insulin values. Insulin and glucose responses during the glucose tolerance test were used for calculation of the incremental plasma insulin values integrated over the 30-min period after the injection of glucose (ΔI) and the corresponding incremental integrated plasma glucose values (ΔG). The rate of glucose disappearance (k) was calculated from the slope of the regression line obtained with log-transformed glucose values from 2 to 15 min after glucose administration.
Islet isolation and perifusion
Rats were anaesthetised by injection of sodium pentobarbital (60 mg ml −1 in 0.9% NaCl; 1 ml kg −1 body weight intraperitoneally) and, once locomotor activity had ceased, pancreases were excised and islets isolated by collagenase digestion. Free islets were collected under a dissecting microscope with a 20 μl pipette into HEPES-buffered Hanks' balanced salt solution containing 5% BSA. Insulin release from freshly isolated islets was measured in a perifusion system as described [15, 24] . In this system, 50 islets were housed in small chambers on Millicell culture plate inserts (Sigma, Poole, Dorset, UK). Islets were perifused in basal medium (Krebs-Ringer containing 20 mmol l −1 HEPES, pH7.4, 5 mg ml −1 BSA and 2 mmol l −1 glucose) for 60 min at a flow rate of 1 ml min −1 at 37°C prior to collection of fractions. Glucose concentrations were then modified as indicated. Fractions (2 ml) were collected at 2-min intervals and stored at -20°C prior to assay for insulin.
Statistical analysis
Results are presented as the means±SEM, with the numbers of rats or islet preparations in parentheses. Statistical analysis was performed by ANOVA followed by Fisher's post hoc tests for individual comparisons or Student's t-test as appropriate (Statview; Abacus Concepts, Berkeley, CA, USA). A p value of <0.05 was considered to be statistically significant.
Results
PPARα activation enables dexamethasone to elicit marked postabsorptive hyperglycaemia in rats maintained on a high-fat diet HF rats treated with dexamethasone (HF-DEX group) did not display significantly higher postabsorptive hyperglycaemia compared with the HF group (Fig. 1a) . PPARα activation by treatment with the PPARα agonist WY14643 did not affect fasting hyperglycaemia in HF rats (Fig. 1b) . In marked contrast, PPARα activation in combination with dexamethasone treatment led to very marked postabsorptive hyperglycaemia in high-fat-fed rats (HF-DEX-WY group) (Fig. 1b) . Postabsorptive glucose levels in the HF-DEX-WY group were 57% higher than those of the HF group, 47% higher than those of the HF-WY group and 41% higher than those of the HF-DEX group.
PPARα activation improves glucose tolerance in dexamethasone-treated high-fat-fed rats Blood glucose concentrations at intervals after an intravenous glucose bolus are shown in Fig. 1a and b. Values of ΔG (the incremental blood glucose values integrated over the 30-min period after the injection of glucose) and k (rate of glucose disappearance) after intravenous glucose challenge are shown in Fig. 1c and d respectively. Dexamethasone treatment of HF rats (HF-DEX group) resulted in a significant loss of glucose tolerance, with significantly increased blood glucose concentrations in HF-DEX rats compared with HF rats at 10 (by 30%; p<0.05), 15 (by 
Interactive effects of dexamethasone and PPARα activation on parameters of glucose tolerance in high-fat-fed rats in vivo. Blood samples were withdrawn from untreated or dexamethasonetreated rats maintained on a high-saturated-fat diet (HF and HF-DEX groups) immediately before (postabsorptive state) and at intervals after an intravenous glucose bolus for measurement of blood glucose concentrations. Subgroups of HF and HF-DEX groups were administered the PPARα agonist WY14643 as a single intraperitoneal injection (50 mg kg −1 body weight), and rats were sampled after a further 24 h (HF-WY and HF-DEX-WY groups). Blood glucose concentrations before and at intervals after an intravenous glucose bolus in the HF (open symbols) and HF-DEX (closed symbols) groups (a) and in the HF-WY (open symbols) and HF-DEX-WY (closed symbols) groups (b). Glucose responses during the glucose tolerance test were used for calculation of the incremental blood glucose values integrated over the 30-min period after the injection of glucose (ΔG). Rates of glucose disappearance (k) were calculated from the slopes of the regression lines obtained with log-transformed glucose values from 2 to 15 min after glucose administration and expressed as % min Results are means±SEM for eight HF, five HF-DEX, six HF-WY and five HF-DEX-WY rats. *p<0.05, **p<0.01 and ***p<0.001 for effects of dexamethasone treatment; † p<0.05 for effects of WY14643 treatment 72%; p<0.05) and 30 (by 39%; p<0.05) min after the glucose bolus (Fig. 1a) , together with a significantly increased ΔG (by 43%; p<0.01) (Fig. 1c) and a significantly decreased k value (by 60%; p<0.001) (Fig. 1d) . PPARα activation in vivo, elicited by the administration of WY14643, did not affect glucose tolerance in HF rats. Thus, blood glucose concentrations, ΔG and k values after an intravenous glucose load were similar in HF and HF-WY rats (Fig. 1) . In contrast, PPARα activation opposed glucose intolerance elicited by dexamethasone treatment of HF rats, as indicated by the decline in ΔG (Fig. 1c) and the increase in the k value for glucose disappearance (Fig. 1d) . Thus, although PPARα activation in dexamethasonetreated HF rats exacerbates hyperglycaemia in the fasted state, it improves glucose tolerance after an acute glucose load.
PPARα activation exaggerates postabsorptive hyperinsulinaemia induced by dexamethasone treatment of high-fat-fed rats and augments glucosestimulated insulin secretion in dexamethasone-treated high-fat-fed rats in vivo Plasma insulin concentrations before and at intervals after an intravenous glucose bolus are shown in Fig. 2a and b . Dexamethasone treatment of HF rats led to increased postabsorptive insulin concentrations to values >5-fold higher (p<0.001) than those of the HF group (Fig. 2a) . PPARα activation did not affect postabsorptive insulin levels in HF rats, but further increased postabsorptive hyperinsulinaemia in dexamethasone-treated, high-fat-fed rats (HF-DEX-WY group) (by 35%; p<0.05) (Fig. 2b) . Insulin responses to acute intravenous glucose challenge in vivo were used for calculation of acute insulin response (AIR) values (means of suprabasal 2-min and 5-min plasma insulin values) (Fig. 2c) and total suprabasal 30-min incremental areas under the curves for insulin (ΔI) (Fig. 2d) . Dexamethasone treatment of HF rats significantly impaired the incremental increase in plasma insulin concentrations 2 and 5 min after the glucose bolus such that the AIR value was suppressed by 37% (p<0.05). Nevertheless, ΔI was unaffected due to significantly higher incremental plasma insulin values at later times (10 and 15 min) after glucose administration (p<0.05) (Fig. 2a) . PPARα activation significantly lowered plasma insulin concentrations 2 and 5 min after the glucose bolus in highfat-fed rats (by 38 and 34%; p<0.05 in both cases) (Fig. 2b) . As a consequence, significant decreases in both AIR (by 39%; p<0.05) and ΔI (by 32%; p<0.05) were observed in HF-WY rats compared with HF rats (Fig. 2c,d) . In marked contrast, PPARα activation in combination with dexamethasone treatment dramatically increased plasma insulin concentrations after the glucose bolus (Fig. 2b) , resulting in significant increases in AIR (by 1.7-fold; p<0.001) and ΔI (by 1.8-fold; p<0.01) values in HF-DEX-WY rats compared with HF rats (Fig. 2) .
Dexamethasone treatment of high-fat-fed rats enhances GSIS in perifused islets, an effect attenuated by antecedent PPARα activation
Contrasting with data obtained in vivo, greatly enhanced peak rates of GSIS were observed ex vivo in perifusions of islets from HF-DEX compared with HF rats (by 2.6-fold; p<0.05) (Fig. 3a) . Furthermore, whereas PPARα activation augmented GSIS in vivo in HF-DEX rats, differences in the GSIS profiles between HF and HF-DEX groups at high glucose were greatly attenuated by PPARα activation (i.e. after WY14643 treatment), indicating partial reversal of the effects of dexamethasone (Fig. 3b) . This implies that the direct effect of PPARα activation on islet function ex vivo is dominant to that of the direct action of glucocorticoids on islet function ex vivo. To allow direct comparison of insulin secretory responses during the step-up and stepdown phases of the islet perifusions, areas under the insulin † AIR (µU . . Corresponding areas under the insulin curves over the equivalent 16-min periods of perifusion after switching to basal glucose are referred to as Δ3 and Δ4. Data are shown in Fig. 4 . Reflecting glucocorticoidinduced increased glucose responsiveness at low extracellular glucose concentrations, Δ1 values for perifused islets from HF-DEX rats were significantly higher (8.3- Fig. 3 Interactive effects of dexamethasone treatment and PPARα activation on glucose responsiveness of insulin secretion by perifused islets from high-fat-fed rats. Islets isolated from the four groups of rats (designations as in Fig. 1 ) were perifused in basal medium containing 2 mmol l −1 glucose for 60 min at a flow rate of 1 ml min −1 at 37°C prior to collection of fractions. Perifusate glucose concentrations were then modified as indicated. Fractions (2 ml) were collected at 2-min intervals and stored at −20°C prior to assay for insulin. Fig. 4 Effects of dexamethasone and/or WY14643 treatment on individual areas under the insulin curves during perifusion of islets from high-fat-fed rats. To allow direct comparison of insulin secretory responses, areas under the insulin curves were calculated for discrete 16-min periods during which the perifusate glucose concentrations were rising: Δ1: perifusate glucose concentration between 2 and 8 mmol l . After exposure to 16 mmol l −1 glucose, perifusate glucose was then lowered to basal levels by switching to basal (2 mmol l −1 glucose) medium. Corresponding areas under the insulin curves over the equivalent 16-min periods of perifusion after switching to basal glucose are referred to as Δ3 and Δ4. a-d Δ1, Δ2, Δ3 and Δ4 values, respectively, for the HF (open bars), HF-DEX (cross-hatched bars), HF-WY (hatched bars) and HF-DEX-WY (closed bars) groups. Data are means±SEM for five HF rats, five HF-DEX rats, five HF-WY rats and five HF-DEX-WY rats. *p<0.05, **p<0.01 and ***p<0.001 for effects of dexamethasone treatment; † p<0.05, † † p<0.01 and † † † p<0.001 for effects of WY14643 treatment PPARα activation to suppress GSIS in HF rats dominates over the effect of dexamethasone to elevate GSIS when GSIS is examined ex vivo.
Dexamethasone treatment of high-fat-fed rats does not affect circulating plasma lipid concentrations, but elevates plasma leptin concentrations To identify potential factors that might suppress GSIS in dexamethasone-treated high-fat-fed rats in vivo, we examined effects of dexamethasone treatment on circulating lipids (which can augment or impair GSIS, depending on the period of exposure) and on leptin, which in general suppresses GSIS. Dexamethasone treatment of high-fatfed rats did not modulate circulating fatty acid concentrations (HF, 0.48±0.08 mmol l −1 , n=9; HF-DEX, 0.53± 0.19 mmol l −1 , n=6) or triacylglycerol concentrations (HF, 0.82± 0.15 mmol l −1 , n=9; HF-DEX, 0.57± 0.18 mmol l −1 , n=6). In contrast, dexamethasone treatment elicited a significant and dramatic 4.8-fold increase in plasma leptin levels (HF, 5.8±1.7 ng ml −1 , n=9; HF-DEX, 28.1±3.6 ng ml −1 , n=6; p<0.001).
Discussion
Normally, in healthy human subjects, changes in insulin sensitivity are compensated by reciprocal changes in GSIS such that the product of insulin sensitivity and insulin secretion remains unchanged (reviewed in [25] ). This is reiterated in Wistar rats fed a high level of saturated fats. Although very long-term (10 months) high-saturated-fat feeding of Wistar rats leads to severe insulin resistance, overt diabetes does not develop [26] . In the highsaturated-fat feeding protocol of Wistar rats used in the present study (female Wistar rats; moderate lipid content; 4 weeks of dietary manipulation), euglycaemic-hyperinsulinaemic clamp studies have demonstrated peripheral insulin resistance, but unimpaired hepatic insulin sensitivity [11] , and enhanced insulin secretion that allows maintenance of glucose tolerance [15] . Glucocorticoids impair glucose homeostasis by opposing insulin's actions to suppress hepatic glucose production and stimulate peripheral glucose uptake. In the present study, we observed that dexamethasone treatment of rats fed a high level of saturated fats elicited glucose intolerance after an acute intravenous glucose challenge. This response was observed in conjunction with fasting hyperinsulinaemia, but a blunted initial response of insulin secretion to a rise in glycaemia. Overall, the GSIS in vivo in response to an acute glucose challenge (ΔI value) was not diminished, but neither was it enhanced sufficiently to prevent glucose intolerance. The finding that GSIS in perifused islets from dexamethasone-treated, high-fatfed rats exceeds that of high-fat-fed rats not treated with dexamethasone implies a degree of islet adaptation for the additional impairment in insulin action introduced by dexamethasone treatment. Our data imply that insulin resistance induced by high-fat feeding is exacerbated by glucocorticoid excess and, although our studies with perifused islets demonstrated that dexamethasone treatment exerts a persistent effect on the islet, which allows augmented GSIS ex vivo, additional factors must operate in the intact organism to oppose the glucocorticoid-induced enhancement of islet insulin secretion that is identified with perifused islets. At present, the identity of these factors remains to be established, but they presumably relate to interactions between increased dietary lipid supply and glucocorticoid excess, interactions which may interrupt the negative feedback loop between insulin sensitivity and secretion in vivo. Although we observed that dexamethasone treatment of high-fat-fed rats did not modulate circulating fatty acid or triacylglycerol concentrations, plasma leptin levels were dramatically increased. Since leptin is known to suppress GSIS [27] it may be involved in uncoupling insulin secretion from insulin action. As the disruption of feedback between insulin sensitivity and secretion in vivo in dexamethasone-treated, high-fatfed rats precipitates the development of glucose intolerance, it reproduces the transition from insulin resistance with islet compensation to type 2 diabetes. In the present study, neither PPARα activation alone nor dexamethasone treatment alone exerted any major influence on fasting glycaemia in high-fat-fed rats. However, marked fasting hyperglycaemia was observed in high-fatfed rats by the combination of dexamethasone treatment and PPARα activation. Hepatic lipid oxidation is augmented by PPARα activation, and this provides ATP and cofactors to sustain or enhance flux through the gluconeogenic pathway, the capacity of which is established to be increased in response to glucocorticoids. Like the action of the glucocorticoids, PPARα activation is an integral component of normal starvation adaptation, as demonstrated from the development of fasting hypoglycaemia in PPARα-null mice [7] . Hence the hepatic adaptation to starvation, namely enhanced hepatic glucose production, may be reproduced by exposure to excess glucocorticoids in combination with PPARα activation under conditions of high-fat feeding, even though dietary carbohydrate is available and energy intake is not compromised, with resultant fasting hyperglycaemia.
PPARα activation enhances insulin sensitivity in peripheral tissues of high-fat-fed rats [16] . This reduces the necessity for compensatory insulin hypersecretion to maintain glucose tolerance [15] . Thus, as shown in the present experiments, PPARα activation in vivo by the administration of WY14643 did not affect glucose tolerance (as reflected by incremental blood glucose values integrated over the 30-min period after the injection of glucose [ΔG] and rates of glucose disappearance [k] values) in HF rats, despite lowered GSIS (which is observed both in vivo after a glucose bolus and ex vivo in islets perifused at high glucose concentrations). Since antecedent PPARα activation in vivo results in a stable lowering of GSIS in perifused islets isolated from high-fat-fed rats, it is implied that increased GSIS in perifused islets from high-fat-fed rats reflects a stable islet adaptation enabling compensatory insu-lin secretion. The observation with ex-vivo perifused islets that antecedent PPARα activation elicits partial reversal of the stable effect of dexamethasone treatment of high-fat-fed rats to augment GSIS is consistent with stable PPARα-induced modification of islet function that opposes augmentation of islet GSIS, which may be linked to improved peripheral insulin action in vivo as a consequence of PPARα activation.
PPARα activation slightly exaggerated the fasting hyperinsulinaemia elicited in high-fat-fed rats in response to dexamethasone treatment. More importantly, in contrast to the data obtained ex vivo using perifused islets, antecedent PPARα activation greatly augmented GSIS in dexamethasone-treated high-fat-fed rats in vivo, such that glucose tolerance was improved. Thus, within the context of highfat feeding, PPARα activation in vivo restores the interorgan operation of the negative feedback loop between insulin action and secretion that is interrupted by dexamethasone treatment.
